Genentech's $94,000-a-Year Drug Tarceva: Why Faster FDA Approvals Could Backfire

By Sam | February 6, 2017

<IMG SRC"http://enewsletters.biospace.com/images/news/biospace-news-815×450-genentech.jpg" NAME"Genentech's $94,000-a-Year Drug Tarceva: Why Faster FDA Approvals Could Backfire" ALT"Genentech's $94,000-a-Year Drug Tarceva: Why Faster FDA Approvals Could Backfire"February 7, 2017By Mark Terry, BioSpace…
Source: BioSpace